(IHE) U.S. Pharmaceuticals - Overview
ETF Category: Health | Exchange: NYSE ARCA (USA) | Market Cap: 870m USD | Total Return: 38.7% in 12m
TER: 0.40%
Avg Turnover: 5.95M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The iShares U.S. Pharmaceuticals ETF (IHE) tracks an index of domestic companies involved in the research, development, and production of vaccines, prescription medications, and over-the-counter drugs. The fund maintains a concentrated, non-diversified portfolio, typically allocating at least 80% of its assets to the physical securities within its underlying benchmark.
The pharmaceutical business model is heavily reliant on intellectual property protections and multi-year clinical trial cycles required for regulatory approval. Companies in this sector often face patent cliffs, where the expiration of exclusive rights allows generic competitors to enter the market and compress profit margins.
Investors can further evaluate the underlying valuation metrics of these pharmaceutical holdings by exploring the data on ValueRay.
- FDA approval cycles for new drug applications drive primary revenue growth
- Patent expirations on blockbuster drugs increase competition from generic manufacturers
- Federal healthcare policy changes influence prescription drug pricing and reimbursement rates
- Research and development expenditures impact long term pipeline viability and margins
- Mergers and acquisitions activity within the pharmaceutical sector accelerates capital appreciation
Over the past week, the price has changed by +0.58%, over one month by +0.42%, over three months by -1.81% and over the past year by +38.73%.
| Analysts Target Price | - | - |